> Pharmaceutical Litigation > Prolia
The osteoporosis drug Prolia has recently been found to increase the risk of atypical bone fractures in the thigh area. From 2010 to 2012, no warning was provided by manufacturer Amgen about this risk.
Prolia, a drug containing denosumab, is given to treat osteoporosis in both men and women, particularly those at high risk of fracture. Prolia is given as a subcutaneous injection of 60 mg every 6 months.
In September 2012, the label on Prolia was updated to include a rare but serious side effect. A small percentage of patients taking Prolia experience fractures of the femur bone. These fractures occur with little or no impact to the thigh area and are found after the patient complains of dull, aching pain in the thigh, hip or groin.
The fracturing of the thigh bone can severely and permanently impact a personâ€™s quality of life, especially those who were taking Prolia to prevent fractures.
If you were taking Prolia, there is a good chance you were not warned about the potential for femur fractures. If you or a loved one has suffered from this complication, you may be eligible for compensation.
If you experienced an atypical fracture after being treated with Prolia, contact the Law Offices of Brian D. Witzer today by calling (888) WITZER-6 for a free, no-obligation consultation. We are here to help you seek justice.